Merck will fund collaborative R&D program for developing "a new class of drugs aimed at altering the course of autoimmune diseases," the Cambridge, Massachusetts immune diseases start-up announced Oct. 6. Merck has agreed to fund the program for up to five years. ImmuLogic has raised approximately $ 28 mil. through three rounds of private funding. Merck was a participant in second round financing and already has another agreement with ImmuLogic concerning vaccine development.
You may also be interested in...
Novavax aims to recruit 10,000 subjects in the UK, and will include a flu vaccination co-administration for some participants.
Accord has launched its first monoclonal antibody biosimilar and fourth biosimilar overall, introducing in the UK the Zercepac version of trastuzumab developed by China’s Shanghai Henlius Biotech.
Alvogen sister company Alvotech is continuing to extend its network of commercial partners by expanding its partnership with DKSH, a Swiss market expansion services group, for the commercialization of six biosimilars in Asian markets.